Kentucky (KY) Buttock Augmentation

Buttock Augmentation Related Terms:
Buttock Augmentation In Kentucky KY, Kentucky Body Procedures, Kentucky Butt, Kentucky Butt Cheeks, Kentucky Buttock Implants, Kentucky Cosmetic Surgery, Kentucky Plastic Surgery

Buttock Augmentation in Kentucky section, includes general infrmation about Buttock Augmentation Procedure, Buttock Augmentation Kentucky Local News, Buttock Augmentation Kentucky Surgeon Locator and other Buttock Augmentation related material.

Buttock Augmentation Procedure

This surgical procedure also called gluteoplasty or buttock augmentation. It is design to reshape the size of your buttocks and create more firm and aesthetic appearance. The buttock area is not easily changed by weight reduction or exercise, therefore you may consider this operation to improve the look of your buttock. In general every person who wishes to undergo the operation and is in a good physical condition can do so.

Buttock augmentation is achieved using fat. The idea is to remove fat from your one body part and inject in into your buttocks. The big advantage of this technique is the fact that there is no rejection since the tissue used is taken from your one body. In addition this method can make your buttock look very natural. The fat is usually taken from areas of the body, which have extra fat, like the flank area, the thigh and the upper and lower buttock. The extra fat, which is removed from the above areas, can further reshape the buttock making it look like you`ve been through a butt lift. After the fat is removed is undergoes some special processing and then injected to your buttocks using a special cannula, which has a very small diameter therefore leaves minimal scars. The big challenge of the fat grafting is to cause the graft to survive in the new place, this can be achieved by injecting small amount of fat each time into different layers, above and below the butt muscles. This way better blood supply is accomplished and irregularities of the surface is minimized. The graft survival is unpredictable, some of the fat is absorbed causing you to loose the augmentation effect. It is generally believed that what`s left after 3 month usually stays forever. After the procedure the buttock area usually don`t heart, the pain is generally from the incisions make in the donor area. Those incisions are also very small, the same ones used for liposuction.

Every procedure has its risks, the risks for this one is minimal. The main risk of the procedure is fat absorption, occurring in approximately one-third of the patients. Bleeding, infection and scarring are rare.

You`ll be able to go back to work after 3-5 days, but you`ll have to wear special garment for 3-4 weeks. It may take up to one month until you feel normal, some swelling may appear, which will usually disappear after a couple of month.

Other Buttock Augmentation Procedures
All Body Procedures
Buttock Augmentation Kentucky (current)
Buttock Augmentation Kentucky Tummy Tuck
Buttock Augmentation Kentucky Calf Augmentation
Buttock Augmentation Kentucky Liposuction
Buttock Augmentation Kentucky Body Contouring

Planing on having buttock augmentation procedure in Kentucky?
Here is some General Information about Kentucky:

Kentucky Regions
Central Kentucky
Eastern Kentucky
Northern Kentucky
North Central Kentucky
South Central Kentucky
Western Kentucky

(WikiT)...

Kentucky buttock augmentation - Tip of the day:

Who are the ones who are going to perform Buttock Augmentation?
The best surgeons in Kentucky(KY) who would perform the operation should be those who have already mastered the art of body procedures, body contouring and fat removal so that there is no cause of worry or fear. They should already have years into this craft and they should know perfectly well what they are doing. Choose carefully so you will be in the safest hands ever with the best surgeons in Kentucky(KY) .

Kentucky buttock augmentation - News update:
A meta-analysis published in the Annals of Internal Medicine has concluded that N-acetylcysteine is the most effective agent for preventing contrast-induced nephropathy in patients with chronic renal insufficiency. However, whether this risk reduction translates into a benefit in clinical outcomes remains to be proven. Researchers conducted a meta-analysis to quantify the effects of individual strategies on the prevention of contrast-induced nephropathy and to facilitate the comparison of preventative effects across strategies. The meta-analysis included 41 trials in which treatment groups received either N-acetylcysteine, theophylline and other agents such as dopamine, fenoldopam, iloprost, statin, furosemide, trimetazidine, bicarbonate, ascorbic acid or mannitol. The primary outcome was the development of contrast-induced nephropathy, defined as an absolute increase in baseline creatinine greater than 44.2 micromol/L or a relative increase greater than 25% at 48 hours after contrast injection. The researchers reported the following results: • N-acetylcysteine decreased the risk for contrast-induced nephropathy compared with saline alone (relative risk 0.62, 95% CI 0.44 to 0.88) • The effects of theophylline on nephropathy were not statistically significant (0.49, 0.23 to 1.06) • Ascorbic acid reduced contrast-induced nephropathy (0.46, 0.23 to 0.90) • Bicarbonate reduced contrast-induced nephropathy (0.12, 0.02 to 0.95) • Furosemide increased the risk of contrast-induced nephropathy (3.27, 1.48 to 7.26) The researchers concluded that pre-procedural treatment with N-acetylcysteine and theophylline reduce the risk of contrast-induced nephropathy, but although theophylline reduces the risk, the reduction is not statistically significant. Additionally, the researchers state that fenoldopam, furosemide and mannitol did not produce beneficial effects. They recommend that the results of this meta-analysis should be evaluated in a head-to-head study to identify the most efficacious regimen for preventing contrast-induced nephropathy. The researchers also mention the following limitations of the meta-analysis: • All trials evaluated surrogate end-points of contrast-induced nephropathy i.e. increase in serum creatinine • Only data from published trials were incorporated More...